Health & FitnessMedicineScienceLife Sciences

The Longevity Podcast: Alzheimer's and Brain Health Research

Dung Trinh

AI-hosted deep dives into the latest Alzheimer's, dementia and brain health research, curated by Dr. Dung Trinh. Each episode breaks down a recent study or topic, such as diet, sleep, exercise, heart health, biomarkers, early detection and new treatments. We explain what the science says and what it may mean for staying sharp as we age.

Episodes are discussions generated with AI hosts. Every episode cites its sources so you can read the original research yourself. This podcast is for education only and is not medical advice. Talk with your doctor about your own health.

Play

Open in

53 episodes
daily
Avg 33 min
English

Episodes 53

Newest Oldest Longest

All20 Unplayed20 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

Yesterday · 19 min
Omega-3 and Memory Decline: The Study Authors Respond to Critics
Send us Fan Mail Did omega-3 supplement use really go along with faster memory decline in older adults? After two letters challenged their ADNI-based study, study authors Liao and Wang reply point by point: how supplement use was measured, which confounders were and weren't covered, why their result differs from earlier work on the same data, and what their brain-scan findings can and can't show. Their bottom line: the link is a signal worth checking, not proof of harm and not a reason to stop supplements or change guidelines. We walk through the back-and-forth and what it teaches about reading nutrition and brain-health research. Source: Liao ZB, Wang YR. "Response to two letters on omega-3 supplementation and cognitive decline." The Journal of Prevention of Alzheimer's Disease, 2026;13(9):100662. DOI: https://doi.org/10.1016/j.tjpad.2026.100662. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
Thursday · 12 min
Omega-3 and Memory: Does the Data Really Show Faster Decline?
Send us Fan Mail Did omega-3 supplements really speed up memory decline in older adults? A recent study using the ADNI cohort suggested they might, contradicting earlier work on the same data that linked omega-3 use to lower Alzheimer's risk. In this letter to the editor, researchers Simon Dyall and Mélanie Plourde dig into why: large amounts of missing data, limited adjustment for key dementia risk factors, and other methodological issues that can make results look very different. We unpack what this debate teaches about reading nutrition and brain-health research. Source: Dyall SC, Plourde M. "Do methodological limitations and confounding factors explain the apparent acceleration of cognitive decline in older adults taking omega-3 fatty acid supplements?" The Journal of Prevention of Alzheimer's Disease, 2026;13(9):100661. DOI: https://doi.org/10.1016/j.tjpad.2026.100661. Licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
Wednesday · 54 min
Midlife Brain Health: Strategies for Mild Cognitive Impairment
Send us Fan Mail What do people in their 40s, 50s, and early 60s with mild cognitive impairment actually do to protect their brain health, and what gets in the way? This scoping review from University College Dublin screened 6,349 records and mapped 17 studies from Asia, Europe, North America, and Africa. Strategies fell into two groups: structured programs such as aerobic exercise, dance, cognitive training, mindfulness, and multi-part lifestyle programs, and everyday self-directed habits such as diet, memory tricks, and mentally stimulating hobbies. We look at what helped people stick with these strategies, what held them back, and the equity gaps the authors found, including few participants from rural or lower-income settings, fewer men, and limited ethnic diversity. Their message: brain health programs should be designed with midlife adults, not just for them. Source: Dookhy J, McCague Y, Hickson J, Stokes D, Kroll T, Frazer K, Brain health strategies in middle-aged individuals with mild neurocognitive disorder: a scoping review, J Prev Alzheimers Dis 2026;13(9):100657. https://doi.org/10.1016/j.tjpad.2026.100657 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
Tuesday · 1 hr 1 min
Dementia Twice as Common in Older Adults Needing Advanced Care
Send us Fan Mail How often does dementia show up in older adults who live at home but need advanced care such as tube feeding, breathing support, catheters, stoma or enema care, wound or pain care, or dialysis? A nationwide survey in Taiwan visited 11,297 community-dwelling older adults between 2020 and 2022. About 6.5% received at least one kind of advanced care, and in that group dementia was more than twice as common (18.0% vs 8.0%). The highest odds were seen with stoma or enema care, tube feeding, dialysis, urinary catheters, and respiratory care. Among people with dementia, day-night confusion and resistance to care were notably more common when advanced care was involved. We talk through what this cross-sectional study can and cannot show, and the authors' message for clinicians and care partners: look for undiagnosed dementia in people with complex care needs, and use patient-centered, non-drug approaches to ease symptoms and caregiver strain. Source: Jhang KM, Tung YC, Wang WF, Chung HJ, Liao HY, Huang LC, Hsu CC, Yang YH, Prevalence of dementia and BPSD in community-dwelling older adults with advanced care needs: a nationwide survey in Taiwan, J Prev Alzheimers Dis 2026;13(9):100656. https://doi.org/10.1016/j.tjpad.2026.100656 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
Monday · 23 min
Alzheimer's Antibody Treatment: How Few Clinic Patients Qualify
Send us Fan Mail New anti-amyloid antibody treatments for early Alzheimer's are now authorized in Europe, but how many patients in a real memory clinic actually qualify? A team in Modena, Italy, applied the Italian appropriate use recommendations step by step to all 1,080 patients seen at their cognitive neurology clinic in 2024 and 2025. Of those, 596 had mild cognitive impairment or mild Alzheimer's dementia, 230 had biomarker-confirmed Alzheimer's, and 50 ended up treatment-ready. That is 4.6% of the clinic, 8.4% of people with a mild clinical diagnosis, and 21.7% of those with confirmed biomarkers. The biggest hurdles were having moved past the mild stage, MRI findings or being unable to have MRI, and care-context needs such as caregiver support for repeated infusions and monitoring. The authors argue that planning should always state which group a percentage refers to, that eligibility screening should start early, and that not qualifying should never mean a withdrawal of care. Source: Zamboni G, Tondelli M, Vinceti G, Gallingani C, Bercini Z, Barbieri A, Carbone C, Iacovino N, Cossutti S, Ballotta D, Salemme S, Chiari A, From regulatory approval to clinical practice: real-world eligibility for anti-amyloid monoclonal antibodies in an Italian dementia-care network, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100655 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
Sunday · 46 min
Social Disadvantage in Midlife Linked to Faster Brain Aging
Send us Fan Mail Can the conditions of everyday life, like money, stress, schooling, neighborhood, and access to care, leave a mark on the brain by age 40? Using the CARDIA study, researchers built a 12-item social determinants of health index across five domains and followed 3,488 adults from early midlife, 645 of them with repeated brain MRI. People in the most disadvantaged group already scored lower on thinking tests at the start. Over each five-year stretch they also showed faster decline in processing speed, faster build-up of white matter hyperintensities (small signs of blood-vessel damage), and faster loss of gray matter volume than the least disadvantaged group. The findings are associations, not proof of cause, and the cohort included only Black and White adults from four U.S. cities. The authors suggest that easing social disadvantage by midlife or earlier may help protect brain health. Source: Dintica CS, Cheunkarndee J, Bryan RN, Launer LJ, Yaffe K, Comprehensive social determinants of health and brain health in midlife, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100652 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 17 · 1 hr 4 min
Loneliness and Stress Linked to Faster Aging on Epigenetic Clocks
Send us Fan Mail Can loneliness, depression, and stress make your body age faster on the inside? Researchers pooled 22 studies of adults from midlife onward that measured "epigenetic age," a biological age estimated from DNA methylation patterns in blood. Greater loneliness, depression, and psychosocial stress were each linked to faster epigenetic aging, most consistently on newer clocks such as PhenoAge and GrimAge that track health and lifespan. The links were modest, and they show association rather than cause. The authors point out that no eligible studies looked at anxiety, that all included studies came from Western countries, and that trials are needed to see whether easing these burdens can slow biological aging. Source: Guo J, Shan J, Ye KX, Liang W, Wang Y, Ang ET, Lee TS, Suckling J, Maier AB, Feng L, Psychological adversities and epigenetic ageing in midlife and older age: A systematic review and meta-analysis, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100650 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 16 · 43 min
When Does Cognitive Decline Begin? Big Study Points to Your 30s
Send us Fan Mail At what age does measurable thinking decline actually begin? Researchers pooled long-term data on 14,389 adults aged 22 to 94 from three population studies in China, the United States, and the Czech Republic, putting different cognitive tests on a common 0 to 100 scale and following people for an average of seven to nine years. A small but detectable drop in overall cognition first showed up in the 31 to 40 age group and grew steadily larger with age. Non-memory skills such as attention and executive function showed change from about age 31, while significant memory decline appeared only after 50. Individual paths varied widely, so age alone did not predict who would decline. The authors say the findings support looking at midlife cognitive monitoring and a life-course approach to brain health, while noting the limits of combining different tests across cohorts. Source: Novotný JS, Klil-Drori S, Geda YE, Nasreddine Z, Stokin GB, Timing of cognitive decline onset and life-course trajectories: A pooled longitudinal analysis of 14,389 adults across three cohorts, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100649 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 15 · 41 min
Brain's Fluid Factory: Choroid Plexus Size and Alzheimer's Pathology
Send us Fan Mail The choroid plexus is the tissue inside the brain's ventricles that makes cerebrospinal fluid and helps clear waste. Earlier imaging studies found it grows larger across the Alzheimer's continuum, but few had checked that against autopsy, the gold standard for diagnosis. Toronto researchers used National Alzheimer's Coordinating Center data on 111 people who had a brain MRI within five years of death and a post-mortem exam. A larger choroid plexus, adjusted for head size, went along with intermediate and high levels of Alzheimer's pathology and with cognitive impairment, while women had smaller volumes than men. Among people with similar high pathology, those with more impairment tended to have larger volumes. The authors say longitudinal imaging and direct measures of fluid flow are needed to understand what drives these changes. Source: Fernandes F, Dey A, Ma A, et al., Choroid plexus volume in pathology-confirmed Alzheimer's disease, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100648 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 14 · 49 min
Dementia Agitation Care: Are Special Care Units Worth the Cost?
Send us Fan Mail Special care units for people with dementia who have agitation and other behavioral symptoms offer a home-like setting with specialized staff. But are they worth the money? The European RECage study followed 508 people for three years across Italy, Switzerland, Germany, Norway, France, and Greece, comparing those cared for in these units with those who were not. Over three years, the special care unit group had slightly fewer quality-adjusted life years (about 0.13 fewer) and roughly €25,000 higher total costs, so the units were likely not cost-effective in this analysis. Because the study was observational and the results are uncertain, the authors say neither widespread rollout nor cutting these units can be recommended yet, and they call for a randomized study stratified by region. Source: Handels R, Michalowsky B, Mendes A, et al., Cost-effectiveness of the special care unit for persons with dementia, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100647 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 13 · 59 min
Cognitive Decline Prediction: Why MRI Models Fail Across Cohorts
Send us Fan Mail Machine learning can forecast how fast thinking skills will slip — but how well do those models work on a new group of patients? Researchers in Zurich trained models on ADNI (1,237 people) and OASIS-3 (662 people) to predict yearly change in CDR-SOB and MMSE scores. Adding structural MRI to clinical and demographic data improved predictions inside each dataset (R² up to about 0.41–0.42 for CDR-SOB). When the same models were tested on the other cohort, performance dropped (R² roughly 0.18–0.35). Slimming the models to only the top predictors did about as well externally, which points to redundant features rather than a free lunch. The paper argues that measuring this generalizability gap is essential before trusting these tools for individual planning. Source: Hüppi RM, Langer N, Vieira BH, Quantifying generalization error in machine learning prediction of cognitive decline, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100646 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 12 · 54 min
Brain Health: Lopsided Memory Centers Signal Decline Without Amyloid
Send us Fan Mail Can the shape of your brain's memory center reveal risk that amyloid tests miss? Researchers at UC Irvine studied MRI scans and up to 10 years of follow-up in 1,142 dementia-free older adults from the Alzheimer's Disease Neuroimaging Initiative. Smaller overall hippocampal volume tracked with worse thinking and faster decline in every area tested. But a bigger size difference between the left and right hippocampus was tied specifically to memory decline, and it predicted progression to dementia only in people without detectable amyloid. The authors suggest hippocampal asymmetry may flag brain changes that go beyond classic Alzheimer's pathology. Source: Ghanbarian E, et al., Hippocampal asymmetry captures non-amyloid-related risk of memory decline and clinical progression, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100638 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 11 · 24 min
Can an Eye Exam Spot Alzheimer's? Retinal Blood Vessels Hold Clues
Send us Fan Mail Could a routine eye exam one day flag Alzheimer's disease? Because the retina is an extension of the brain, this study used a genetic method called Mendelian randomization, drawing on large genetic datasets and more than 52,000 UK Biobank participants, to sort out which eye changes Alzheimer's actually causes. Genetic risk for Alzheimer's was linked to more twisted small arteries in the retina, with weaker hints of thinning in the inner retinal layers. An apparent link between optic disc size and Alzheimer's was probably explained by refractive error. The authors say more work is needed before eye screening for dementia is ready for the clinic. Source: Kiser H, et al., Can we identify people with Alzheimer's disease from examination of the eye? A bidirectional Mendelian randomization (MR) study, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100635 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 10 · 36 min
Brain Health: Fluid Spaces on MRI Reveal Amyloid vs Vascular Damage
Send us Fan Mail Enlarged perivascular spaces, the fluid-filled channels around small blood vessels in the brain, show up on routine MRI. This study of 307 people with cognitive impairment from a Seoul dementia cohort asked whether amyloid and blood vessel disease leave different patterns of these spaces. Vascular burden was linked to more enlarged spaces deep in the basal ganglia, regardless of amyloid. Amyloid and vascular disease were each linked to more spaces in the parietal, temporal, and occipital white matter, with no extra increase when both were present. The spatial pattern may help hint at which pathologies are driving cognitive impairment. This episode is an AI deep-dive overview of the open-access paper. It sticks to what the study reports. Source: Kim W, et al., Distinct spatial patterns of perivascular spaces enlargement for multiple and co-existing pathologies of cognitive impairment, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100631 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 8 · 30 min
Dementia Stages: How a Daily Function Test Tells Mild From Moderate
Send us Fan Mail How do clinicians tell mild dementia from moderate dementia? This study tested the Functional Activities Questionnaire, an informant-based checklist of everyday tasks, in more than 34,000 people from the US NACC database and confirmed the results in the ADNI and FTLDNI cohorts. A score of 18 or higher caught 96% of moderate dementia cases, while a cut-off of 23 traded a little sensitivity for higher specificity. Older age and lower cognitive scores made misclassification more likely. Source: Ersözlü E, et al., Drawing a line: Differentiating mild from moderate dementia using the functional activities questionnaire, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100630 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 7 · 32 min
Alzheimer's Timeline: Amyloid to Tau Is Faster in Women, APOE4
Send us Fan Mail Using amyloid and tau PET scans from two US cohorts, ADNI and the Harvard Aging Brain Study, researchers estimated how long it takes to go from amyloid positivity to tau positivity. That interval varied widely and was shorter in APOE4 carriers, women, and people who became amyloid positive at older ages. A shorter amyloid-to-tau interval predicted earlier symptom onset, pointing to a narrower window for early detection in these groups. Source: Milà-Alomà M, et al., The time interval from amyloid to tau PET positivity varies by age, sex and APOE-ε4 status, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100622 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 6 · 49 min
Gut Molecule ImP Linked to Faster Alzheimer's Decline
Send us Fan Mail A gut bacterial compound called imidazole propionate (ImP) is linked to Alzheimer's-related brain changes and faster cognitive decline in a large Wisconsin cohort, with mouse and cell studies pointing to barrier and tau pathways. Researchers measured blood ImP in nearly 1,200 mostly cognitively unimpaired adults, connected ImP-producing gut bacteria to disease markers, and found a genetic signal tied to both ImP levels and Alzheimer's risk. In mice, chronic ImP worsened Alzheimer-like pathology. This episode is an AI deep-dive overview of the open-access Nature Communications paper. It sticks to what the study reports. Source: Vemuganti V et al., Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology. Nat Commun. 2026. doi:10.1038/s41467-026-74744-z (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 5 · 37 min
Alzheimer's Blood Proteins: How MRI Links Them to Risk
Send us Fan Mail A Mendelian randomization study of plasma proteins, structural MRI measures, and Alzheimer's disease risk found 12 neuroimaging metrics and 1,633 proteins with causal ties to AD. Brain imaging also mediated about 67% of the link between the immune-related protein PTPRC and Alzheimer's risk across the disease course. Source: Xu X, et al., Bidirectional causal relationships between plasma proteins, neuroimaging metrics and risk of Alzheimer's disease, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100619 (CC BY 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 4 · 46 min
Dementia Safety Risks: Medication Errors Top China Study
Send us Fan Mail A China-wide survey of 1,057 older adults with Alzheimer's or related cognitive impairment found 73.5% had at least one safety incident in the past year, and over a third reported three or more. Medication errors and verbal aggression were the most common, followed by falls and physical aggression. Medication errors and getting lost also sat at the center of how different incidents linked together across care settings and regions. Source: Zhou Y, et al., Mapping the nature, type, and association network of safety incidents among individuals with cognitive impairment in China: a large-scale multicenter cross-sectional study, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100606 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters
October 3 · 19 min
Alzheimer's Drug Safety: Why Blood Thinner Exclusions Matter
Send us Fan Mail A letter in JPAD argues that a reported safety advantage for an anti-amyloid antibody drug, in a European-label subgroup of its phase 3 trial, may largely reflect excluding patients on blood thinners. About one in four people with Alzheimer's take those medicines in real-world data, so the subgroup findings may not apply in everyday practice. Source: Ijaz A, Mohyudin G, The generalizability gap: anticoagulant exclusions and the "Enhanced Safety" of donanemab in the EU-eligible population, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100628 (CC BY-NC-ND 4.0) This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!
- Transcript
- Chapters

Showing 1–20 of 53 episodes